Kilauea Volcano on Hawaii erupts for 25th time since December, spewing lava 330 feet high: "Here we go again!"
One of the world's most active volcanoes, Kilauea on Hawaii's Big Island, began spewing lava from the north vent Wednesday, the latest event in an ongoing eruption that began almost six months ago.
Lava fountains reached heights of more than 330 feet and feeding multiple lava streams. Scientists with the U.S. Geological Survey's Hawaiian Volcano Observatory said the fountains were likely to go higher.
"Here we go again!" the observatory wrote on its Facebook page.
This image from webcam footage provided by the United States Geological Survey (USGS) shows lava fountains shooting up high in the latest episode of an ongoing eruption of Kilauea volcano inside Hawaii Volcanoes National Park on Wednesday, June 11, 2025.
United States Geological Survey via AP
The latest event was preceded by gas-pistoning, in which gas accumulates at a lava column's top within a vent, on Tuesday.
The observatory said this process causes the lava surface to rise or piston. "Eventually, gas escapes as splatter/lava is erupted, and lave drains back into the vent," the observatory wrote.
These were occurring up to 10 times an hour, but increased in intensity until a small, sustained dome fountain began to feed flows to the crater floor a day later.
The USGS has set up three Kīlauea summit livestream videos, which can be seen here.
It is the 25th eruptive episode since the volcano on the southeastern part of the island began erupting Dec. 23. It has been pausing and resuming since.
Most of the eruptive episodes have spewed lava for about a day or less, with pauses between them generally lasting a few days.
The USGS warned that high levels of volcanic gas can have far-reaching effects downwind. Sulfur dioxide (SO2) reacts in the atmosphere to create the visible haze known as vog (volcanic smog), which may cause respiratory and other problems, the agency said.
Additional hazards include Pele's hair (strands of volcanic glass often produced by lava fountaining activity) and other volcanic fragments that can fall on the ground within a few hundred yards of the eruptive vents, the USGS said.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
21 minutes ago
- Bloomberg
NASA Considers Launching Astronaut Mission Next Week After Delay
NASA is considering launching its fourth astronaut mission to the International Space Station as early as next Thursday after a repair review caused a delay. NASA has looked into repair efforts for what it described as small leaks in a service module at the ISS. NASA, Axiom Space, and Elon Musk's SpaceX are now reviewing launch opportunities as soon as June 19, it said in a statement.
Health Line
an hour ago
- Health Line
HIV: As Scientists Inch Closer to a Vaccine, Cuts to Funding Could Stall Progress
The Trump administration reportedly plans to cut almost all funding for HIV vaccine research. Experts say the decision comes at a time when research in this field is making substantial progress. Many effective treatments are available for HIV, but these are lifelong commitments that manage a chronic disease rather than cure it. Treatments for HIV infection have come a long way since the 1980s, when too many lives were lost during the epidemic. Today, antiretroviral therapies and other treatments allow people with HIV to live longer lives and, in many cases, prevent the transmission of the virus that causes the disease to other people. Scientists now say the next step in the fight is a vaccine that protects against HIV. However, that next development could be on the chopping block. Trump administration officials reportedly plan to halt funding for a wide array of HIV vaccine research. Researchers told CBS News they have been informed by officials at the National Institutes of Health (NIH) that the Department of Health and Human Services (HHS) has instructed the agency not to issue any more funding during the next fiscal year for HIV vaccine research. NIH officials said HHS officials have instead decided to 'go with currently available approaches to eliminate HIV.' The decision will close down HIV vaccine research projects at the Duke Human Vaccine Institute and the Scripps Research Institute, according to a report in the journal Science. Officials at Moderna also told CBS News that their current clinical trials on HIV vaccines have been put on hold. Experts say the decision to cut funding for an HIV vaccine is short-sighted and reckless. 'I'm stunned by this decision,' said Jake Scott, MD, a clinical associate professor of medicine at Stanford University in California who specializes in infectious diseases. 'There is no scientific or medical evidence to justify these cuts at the exact moment this field is showing real promise,' he told Healthline. Carl Baloney Jr., the chief executive officer-elect of AIDS United, agreed. 'Eliminating funding for HIV vaccine research undermines decades of scientific progress and turns our back on a future where HIV could be preventable for all, regardless of where someone lives, their income, or access to healthcare,' he told Healthline. Why an HIV vaccine is important Experts say that treatments for HIV are incredibly effective. However, they note that most involve daily adherence and aren't necessarily readily available or affordable for many people. 'There are a lot of good options, but they can be really expensive,' Scott said. 'These medications are also not a cure. They are a lifetime burden.' The experts add that people with low levels of HIV in their system can still have weakened immune systems. That can raise the risk of serious infections as well as inflammation that can lead to conditions such as heart disease. 'A vaccine can help prevent all this,' said Scott. Experts note that a vaccine research program may be difficult to put back together even if a new administration restored funding in the near future. They say it took decades to build these programs and restarting them would take time. In addition, researchers will leave the field of HIV prevention to set up shop in another industry that is receiving funding. 'We could lose an entire generation of scientists,' said Scott. 'This is setting the field back a decade or more at a critical time.' 'This isn't just about canceling [a] clinical trial. It's about sidelining the scientists, institutions, and community partners driving innovation forward,' added Baloney. 'These setbacks could delay the development of a successful HIV vaccine by years or even decades.' How scientists fought against HIV The first treatment for HIV was approved by the Food and Drug Administration (FDA) in 1987. Azidothymidine (AZT) was first developed in 1964 as a treatment for cancer. It was ineffective in that usage, but in the 1980s, scientists discovered AZT could suppress HIV replication without damaging healthy cells. It helped treat people with AIDS as well as people who were HIV positive but had no symptoms. In the 1990s, other nucleoside reverse transcriptase inhibitors (NRTIs) were developed and approved. Laboratory tests to measure viral load and cell counts accelerated this research. From there, scientists experimented with combining drugs to help counter the HIV virus's ability to mutate and replicate. In 1996, a triple-drug therapy proved effective in thwarting HIV replication and creating a barrier against drug resistance. Since then, these antiretroviral drugs have become more effective and more available. The effectiveness of these medications is nothing short of miraculous. In the 1980s, the average life expectancy after an AIDS diagnosis was one year. Today, people who adhere to combination antiretroviral drug therapies can expect to live a near-normal life span. In some cases, the medications can reduce the HIV viral load in a person to the point where the virus is undetectable and can't be transmitted to another person. How is HIV treated today? More than 50 types of HIV medications are now approved for use. Some of the more commonly used antiretroviral medications are: Combination NRTI drugs that include Truvada and Descovy. These medications work by preventing HIV from converting its RNA into DNA. This prevents the virus from making copies of itself.. Integrase strand transfer inhibitors (INSTIs) that include Vocabria and Biktarvy. These drugs work by blocking an enzyme that HIV uses to put HIV DNA into human DNA inside cells. Protease inhibitors (PIs) such as Lexiva and Crixivan. These medications work by blocking an enzyme that HIV needs as part of its life cycle. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) that include Intelence and Viramune. These drugs work by preventing the HIV virus from making copies of itself. Entry inhibitors such as Fuzeon and Selzentry. These medications work by blocking HIV from entering CD4 T cells. In addition, there are drugs known as Cytochrome P4503A (CYP3A) inhibitors, such as Tybost and Norvir, that help boost the levels of HIV medications in the bloodstream. There are also medications known as post-attachment inhibitors that when used with antiretroviral drugs can help prevent HIV from entering immune cells. Trogarzo was the first of these drugs to become available, having been approved in 2018. In addition, there are attachment inhibitor medications, a newer form of HIV drug that works by attaching to a viral protein, which prevents that protein from entering healthy T cells. Only one type of this medication, Rubokia, is currently available, having been approved in 2020. Most people with HIV are given medications, but there also are long-acting injections that are given once a month or once every other month. Scott said these treatments are cures that have turned HIV into a 'managed chronic disease' to the point where he and other colleagues now refer to AIDS as 'advanced HIV.' Baloney said, however, there are limits to how much treatments can do. 'Current treatments and prevention tools have transformed HIV into a manageable chronic condition, but they are not a cure and they're not accessible to everyone,' he said. 'An HIV vaccine would be a game-changer, especially for communities facing systemic barriers to care.' Preventive measures for HIV Even with the available treatments, experts agree that it's better for a person if they don't contract HIV in the first place. They say condom use, along with dental dams and gloves, can be effective barriers to contracting HIV. Limiting sexual partners is also recommended, as are sterile needles for intravenous drug users. Getting tested for HIV is also an important component. It's estimated that more than 1 million people in the United States have HIV, and 13% of them don't know they have contracted the virus. There are medications available that can be taken as a precaution or after potential exposure to HIV. These drugs include: Preexposure prophylaxis (PrEP): These medications can be taken as a daily pill or a bimonthly injection. The first injectable PrEP drug was Apretude, which was approved by the FDA in 2021. Truvada can also be used as PrEP therapy. These medications help prevent HIV from getting a foothold in the body. Postexposure prophylaxis (PEP) drugs: These are designed to be taken within 72 hours of potential exposure to HIV. It is a pill ingested once a day for 28 days. Lenacapavir: This injectable drug has been tested in clinical trials as a potential PrEP therapy. The FDA is scheduled to vote on its approval on June 19. Experts say all these preventive measures are good practices, but they note that vaccines are still the most effective.
Yahoo
an hour ago
- Yahoo
Scientists invent way to make farmed salmon healthier and better for you
Scientists have invented a way to make farmed salmon healthier. Feeding fish with a new type of rapeseed oil, which includes a natural red pigment, makes pink seafood richer in omega-3 oils and filled with more antioxidants, a study has found. The pinkness of a fish, whether shrimp, trout or salmon, comes from consumption of a chemical called astaxanthin, which is produced by some algae in the wild. Wild fish eat this in their diet and become pink as a result, but farmed fish do not and as a result have naturally grey flesh. These fish are therefore fed synthetic versions of this chemical to make the aesthetically pleasing hue consumers desire. But a genetically modified variant of the crop, which is spliced with genes from the scarlet flax flower, creates a plant that naturally produces seeds rich in astaxanthin. DNA, which powers the pigment-making pathway, was injected into the crop's own genome and small batches were grown at trial sites in the US and UK. Published in the Plant Biotechnology journal, data show that in each gram of seed from this new crop, there are 136 micrograms of colourful pigments. More than a third (47 micrograms) is astaxanthin. Giving this to fish in their diet to make them pink, instead of the current synthetic astaxanthin, would make the salmon healthier and better to eat, scientists say. In another experiment by the same scientists at Rothamsted University, oil made from these plants was given to 120 rainbow trout in four tanks. The study was later published in the journal Aquaculture. These animals grew just as big and were richer in health chemicals such as omega-3, the study found. Prof Johnathan Napier, a plant biotechnology pioneer who led the work at Rothamsted, told The Telegraph: 'The plant-based source of the pigment is accumulated and delivers benefits to the fish. 'In particular, it can help reduce the build-up of pro-inflammatory molecules. 'We are also hoping to see if having diets in which the plant-derived astaxanthin is present makes them more resistant to disease (especially lice) and stress – that work is ongoing.' The fish which eat the new oil are healthier, he said, and the humans that eat the fish are also set to benefit from the change. Prof Napier said: 'One would hope that fish being fed this diet would be more healthy [sic],' 'Astaxanthin helps to reduce oxidation, and therefore protects the fish's metabolic state as well as protecting the healthy omega-3s and then we consume and get health benefits for ourselves. 'And there is also an additional potential benefit from having the astaxanthin in your diet, as an antioxidant.' The scientists who invented the new plant used genetic modification techniques to create the astaxanthin-rich rapeseed oil. It is not possible to grow this crop commercially in the UK because the UK still uses the EU legislation prohibiting genetically modified (GM) foods. GM foods are allowed in the US and Prof Napier believes fish and farmers over there will be able to benefit from this new product in less than ten years. Red tape around the use of GM foods in UK agriculture, he believes, is stifling the market and also preventing foods which Prof Napier said: 'Tax revenue is being used to fund millions of pounds' worth of fundamental research in UK universities and institutes. 'But the potential arising from any useful discoveries is not correctly captured or exploited because of regulatory burdens. 'In the specific example of GM crops, we are still lumbered with the EU regulations, so we are double-whammied.' Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
